Arexvy▼ (Respiratory Syncytial Virus (RSV) vaccine (recombinant, adjuvanted)
Not a healthcare professional? Visit our Public site
Not a healthcare professional? Visit our Public site
Date of preparation: September 2023 PM-IE-SGX-WCNT-230004
Get access to exclusive events on the topics that matter to you, free patient resources including patient support materials, demo devices and updates on the latest in HIV/AIDS, respiratory, oncology and Vaccines
References
Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.
▼ These medicinal products are subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
Trade marks are owned by or licensed to the GSK group of companies.
PM-IE-NA-WCNT-220010 Date of Preparation: September 2024